Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study

Hematological Oncology

Volumn 31, Issue 4, 2013, Pages 179-182

  Zinzani, Pier Luigi ^a   Pellegrini, Cinzia ^a   Merla, Emanuela ^b   Ballerini, Filippo ^c   Fabbri, Alberto ^d   Guarini, Attilio ^e   Pavone, Vincenzo ^f   Quintini, Gerlando ^f   Puccini, Benedetta ^g   Vigliotti, Maria Luigia ^h   Stefoni, Vittorio ^a   Derenzini, Enrico ^a   Broccoli, Alessandro ^a   Gandolfi, Letizia ^a   Quirini, Federica ^a   Casadei, Beatrice ^a   Argnani, Lisa ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f Unit of Hematology   (Italy)

^g Policlinico di Palermo ^*  (Italy)

^h Unit of Oncology and Hematology   (Italy)

Author keywords

Bortezomib; Observational; Relapsed lymphoma; Retrospective

Indexed keywords

BORTEZOMIB; CISPLATIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; IBRITUMOMAB TIUXETAN; RITUXIMAB;

ANEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INDOLENT NONFOLLICULAR LYMPHOMA; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BORTEZOMIB; OBSERVATIONAL; RELAPSED LYMPHOMA; RETROSPECTIVE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OFF-LABEL USE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN KINASE INHIBITORS; PYRAZINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84889084747     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2036     Document Type: Article

References (26)

1. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009; 14: 17-29.
2. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009; 94: 1488-1492.
3. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappaB. Cell 1994; 78: 773-785.
4. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
5. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008; 22: 179-185.
6. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427.
7. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
8. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009; 146: 652-655.
9. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
10. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-2112.
11. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
12. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520-525.
13. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116-121.
14. O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009; 145: 34-39.
15. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076.
16. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690-697.
17. O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010; 16: 719-726.
18. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27: 5023-5030.
19. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010; 115: 475-480.
20. Coiffier B, Osmanov E, Hong X, et al. A Phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive, follicular lymphoma. Blood 2010; 116: (ASH Annual Meeting Abstracts). Abstract 857.
21. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
22. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
23. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
24. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer, Published online December 14, 2010; doi:10.1002/cncr.25792.
25. Chiappella A, Pregno P, Zinzani PL, et al. The combination of bortezomib and rituximab is effective and safe in relapsed/refractory indolent nonfollicular and mantle-cell non-Hodgkin lymphoma: a phase II multicenter study by Intergruppo Italiano Linfomi [abstract]. Blood 2009; 114: (ASH Annual Meeting Abstracts). Abstract 3758.
26. Richardson PG. Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. Lancet Oncol 2010; 11: 1014-1016.